Claims for Patent: 8,735,076

Summary for Patent: 8,735,076

Title:	Targets for use in diagnosis, prognosis and therapy of cancer
Abstract:	Provided herein are targets that can be used for the diagnosis, prognosis and therapy of a variety of cancers.
Inventor(s):	Eng; Charis (Cleveland Heights, OH), Weber; Frank (Essen, DE)
Assignee:	The Cleveland Clinic Foundation (Cleveland, OH)
Application Number:	13/418,310
Patent Claims:	1. A method of diagnosing PTEN Hamartoma Tumor Syndrome (PHTS) or susceptibility to PHTS in an individual comprising a) performing a haplotype analysis on a sample of the individual's PTEN locus, and b) detecting increased linkage disequilibrium in at least one haplotype block at the individual's PTEN locus, wherein the haplotype block is selected from the group consisting of a block 1 haplotype, a block 2 haplotype, a block 3 haplotype and a combination thereof, compared to a control, wherein the presence of the increased linkage disequilibrium in the at least one haplotype block is indicative of a diagnosis of PHTS or a susceptibility to PTHS in the individual. 2. The method of claim 1 wherein the PHTS is selected from the group consisting of Cowden Syndrome, Bannayan-Riley-Ruvalcaba Syndrome, Proteus Syndrome, Proteus-Like Syndrome and a combination thereof. 3. The method of claim 1 wherein the individual is PTEN mutation negative, PTEN mutation positive or PTEN variation positive. 4. The method of claim 3 wherein the individual is PTEN mutation positive or PTEN variation positive and the haplotype block 1 comprises the sequence GACCCTCGI (SEQ ID NO: 19). 5. The method of claim 1 wherein the at least one haplotype block is detected in a nucleic acid sample obtained from the individual. 6. The method of claim 1 wherein the individual is a human. 7. The method of claim 1 wherein increased linkage disequilibrium is detected in haplotype block 1, haplotype block 2 and haplotype block 3. 8. The method of claim 1 wherein detection of linkage disequilibrium comprises detection of one or more of SEQ ID NOs: 19-35 in one or more of the haplotype blocks. 9. The method of claim 1 wherein the control is one or more PTEN loci from one or more PHTS negative individuals. 10. A method of diagnosing PTEN Hamartoma Tumor Syndrome (PHTS) or susceptibility to PHTS in an individual a human that is PTEN mutation negative comprising (a) performing a haplotype analysis of on a sample of the individual's PTEN locus; and (b) detecting increased linkage disequilibrium in at least one haplotype block in the PTEN gene spanning a region upstream of the PTEN gene and the first intron of the PTEN gene, compared to a control, wherein the at least one haplotype block in the PTEN gene spans about 33 kb from about position 89,583,605 to about position 89,616,359 on human chromsome 10, wherein increased linkage disequilibrium at the haplotype block is indicative of a diagnosis of PTEN Hamartoma Tumor Syndrome in the human. 11. The method of claim 10 wherein the control is one or more PTEN loci from one or more PHTS negative individuals. 12. The method of claim 10 further comprising detecting increased linkage disequilibrium in (i) a haplotype block spanning about 65 kb from about nucleotide position 89,629,942 to about 89,694,699 in the PTEN locus on human chromosome 10, (ii) a haplotype block spanning about 43 kb from nucleotide position 89,702,453 to about 89,745,623 in the PTEN locus on human chromosome 10, or (iii) a combination thereof, compared to a control. 13. The method of claim 10 wherein the PHTS is selected from the group consisting of Cowden Syndrome, Bannayan-Riley-Ruvalcaba Syndrome, Proteus Syndrome, Proteus-Like Syndrome and a combination thereof. 14. The method of claim 10 wherein the at least one haplotype block is detected in a nucleic acid sample obtained from the individual. 15. The method of claim 10 wherein the haplotype block comprises a GACCCTCGI sequence (SEQ ID NO: 19). 16. The method of claim 10 wherein detection of linkage disequilibrium comprises detection of one or more of SEQ ID NOs: 19-35 in one or more of the haplotype blocks.

Details for Patent 8,735,076

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26